Poon Christine A's Form 4 filing
Regeneron Pharmaceuticals, Inc.REGN · filed Nov 4, 2026
- Accession no.
- 0001189014-26-000009
- Filed
- Nov 4, 2026, 4:09 PM ET
- Trade date
- Nov 2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 7 non-derivative transactions and 1 derivative transaction. Open-market sales total $7.59M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Poon Christine ACIK 0001189014 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Common Stock | MOption exerciseAcquired | +7,830 | $376.69 | +$2,949,482.7 | 13,049 | Direct | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −218 | $966.74F1 | −$210,749.32 | 12,831 | Direct | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −772 | $967.38F2 | −$746,817.36 | 12,059 | Direct | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −2,499 | $968.58F3 | −$2,420,481.42 | 9,560 | Direct | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −3,203 | $969.50F4 | −$3,105,308.5 | 6,357 | Direct | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −937 | $970.51F5 | −$909,367.87 | 5,420 | Direct | |
| Nov 2, 2026 | Common Stock | SSaleDisposed | −201 | $971.31F6 | −$195,233.31 | 5,219 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Common Stock | MOption exerciseDisposed | −7,830 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents volume-weighted average price of sales of 218 shares of Company stock on November 2, 2026 at prices ranging from $966.39 to $966.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F2
Represents volume-weighted average price of sales of 772 shares of Company stock on November 2, 2026 at prices ranging from $967.06 to $967.75. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
Represents volume-weighted average price of sales of 2,499 shares of Company stock on November 2, 2026 at prices ranging from $968.00 to $968.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
Represents volume-weighted average price of sales of 3,203 shares of Company stock on November 2, 2026 at prices ranging from $969.01 to $969.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F5
Represents volume-weighted average price of sales of 937 shares of Company stock on November 2, 2026 at prices ranging from $970.00 to $970.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
Referenced by the price of 1 transaction in Table I.
- F6
Represents volume-weighted average price of sales of 201 shares of Company stock on November 2, 2026 at prices ranging from $971.16 to $971.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 2, 2026 at each separate price.
Referenced by the price of 1 transaction in Table I.